Eli Lilly and Company
LLYEquityAI Summary
Updated 6h ago
Eli Lilly and Company (LLY) has lost significant upward energy
Eli Lilly and Company (LLY) has lost significant upward energy. Momentum indicators are at historically low levels across multiple timeframes — sellers have had the upper hand recently. For reference: Flow Score 18/100, Trend & Momentum Score 16/100.
Market Positioning
What's Happening
Lilly raised full-year guidance after blockbuster Q1
On 2026-04-30, Eli Lilly raised its 2026 revenue outlook to $58.0 billion to $61.0 billion from $58.0 billion to $61.0 billion? Wait, the company actually guided 2026 revenue to $82.0 billion to $85.0 billion and non-GAAP EPS to $35.50 to $37.00 after Q1, according to its earnings call. That matters because management is signaling demand for Mounjaro and Zepbound is still outrunning supply and pricing pressure, which gives the market a cleaner read on operating leverage than a simple EPS beat.
The Bigger Picture
Macro context will be updated shortly
Upcoming Catalysts
Updated 90d agoThis is the next major check on whether Lilly can defend the full-year guidance it raised after Q1. Watch for updated commentary on demand for Mounjaro and Zepbound, realized pricing, and whether capacity expansion is keeping pace with sales.
If Lilly changes its 2026 revenue or EPS ranges, that will likely be the most important market-moving detail in the release. Investors will focus on whether management keeps the current $82.0 billion to $85.0 billion revenue range and $35.50 to $37.00 EPS range intact.
Technical Analysis
Market Positioning
Where does this asset sit across four dimensions? Extension (how stretched price is vs its own history), Momentum (RSI, MACD, rate of change), Flow (volume and money flow), and Volatility (how quiet or active). Each bar shows a 0–100 percentile compared to the last year of data. Key levels show the nearest demand and supply zones from our confluence analysis.
Key Levels
Looking at the full picture for Eli Lilly and Company (LLY): extension is below average (16th percentile), momentum is deeply below average — at historically low levels (5th percentile), flow is deeply below average — at historically low levels (8th percentile), volatility is slightly below average (41st percentile). All three directional dimensions — extension, momentum, and flow — are in the lower portion of their historical ranges. The asset is under broad pressure, with price compressed, upward energy depleted, and selling pressure elevated. There is no positive divergence to point to. The key to watch is whether flow stabilises above the 40th percentile while extension remains compressed. That combination would represent a historically more significant setup.
Where is money flowing?
Trend
Is momentum building or fading?
What is the relative strength?
How extended is this move?
Where are the key levels?
What risk am I taking?
Conclusion
Eli Lilly and Company (LLY) is under broad pressure across multiple dimensions — extension, momentum, and flow are all in the lower portion of their historical ranges. There is no positive divergence to point to at this stage. If extension drops further into the lower teens while flow holds above the 40th percentile, that would represent a historically more significant setup. These readings update daily. Flipside shows what is happening now, grounded in the data — not what will happen next.
Your portfolio. Your context. Smarter decisions.
Connect your holdings and let the Flipside Agent analyze market changes through the lens of your portfolio.
Personalized insights based on your actual holdings
Major market movements delivered to your inbox
Track the assets that matter most to you
No credit card required